Posters and Presentations
04/05/25
Comparative Effectiveness of Troriluzole versus Untreated Natural History Cohorts in Spinocerebellar Ataxia (SCA) Leveraging Propensity Score Matching Methods
04/05/25
Incorporating Patient Perspectives into a Composite Score for Measuring Disease Progression in Spinocerebellar Ataxia (SCA)
11/12/2024
Patient Concept Elicitation Interviews: Insights Into Spinocerebellar Ataxia Patient Experiences
11/12/2024
Comparison of Two Matching Methods to Assess Effectiveness of Troriluzole versus Untreated Natural History Cohort in Spinocerebellar Ataxia
5/29/2024
Two Randomized, Double-Blind, Placebo-Controlled Trials of Troriluzole, A Novel Glutamate Modulating Agent, in Obsessive-Compulsive Disorder
04/14/2024
Population Pharmacokinetic Modeling of Riluzole After Administration of a Next Generation Prodrug Troriluzole
04/14/2024
Next Generation Prodrug Troriluzole: Increased Bioavailability of Riluzole with No Food Effect in Healthy Subjects
04/15/2024
Troriluzole Exhibits Favorable Hepatic Safety Profile Across a Diverse Range of Disorders
04/15/2024
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Rising Doses of a Next Generation Prodrug Troriluzole in Healthy Subjects
04/15/2024
No Clinically Relevant Effects of Hepatic Impairment on the Pharmacokinetics of a Next Generation Prodrug Troriluzole
04/16/2024
Automated Video-based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects with Spinocerebellar Ataxia
04/16/2024
Psychometric Validation of the Modified-functional Scale for the Assessment and Rating of Ataxias
04/16/2024
Development of a Novel Composite Measure (SCACOMS) to Assess Disease Progression in Spinocerebellar Ataxia
04/17/2024
Matching-adjusted Indirect Comparison of Troriluzole Versus Untreated Natural History Cohort in Spinocerebellar Ataxia
9/12/2023
Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6: Self-Reported Functional Status and Quality of Life
10/16/2023
Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6 through the Eyes of Patients: Burden of Illness and Quality of Life
3/3/2024
Content Validity of the Friedreich’s Ataxia Rating Scale – Activities of Daily Living (FARS-ADL) for Use in Patients With Spinocerebellar Ataxia (SCA)
3/3/2024
Measurement Properties of the Friedreich’s Ataxia Rating Scale–Activities of Daily Living in Patients With Spinocerebellar Ataxia
3/3/2024
Automated Video-Based Characterization of Movement Quality in a Phase III Clinical Trial of Troriluzole in Subjects With Spinocerebellar Ataxia
3/4/2024
Understanding the Spectrum of SCA1, SCA2, SCA3 & SCA6 through the Eyes of Patients: Burden of Illness and Quality of Life
5/25/2023
Understanding the Spectrum of SCA1, SCA2, SCA3, and SCA6 Through the Eyes of Patients: Burden of Illness Perspectives.
6/1/2023
Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder
11/17/2022
Two Randomized, Double-Blind, Placebo-Controlled Trials of Adjunctive Troriluzole, a Novel Glutamate-Modulating Agent, in Obsessive-Compulsive Disorder
02/23/25
Taldefgrobep Alfa Inhibition of Activin II Receptor Signaling Drives Lipid Oxidation and Muscle Growth, Providing a Novel Therapeutic Approach to Obesity
6/22/2024
Taldefgrobep Alfa Improves Body Composition as Monotherapy and in Combination With Semaglutide in a DIO Mouse Model
06/20/2023
Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy
03/20/2023
Taldefgrobep Alfa: Preclinical and Clinical Data Supporting the Phase 3 RESILIENT Study in Spinal Muscular Atrophy
04/05/25
A Qualitative Assessment of the Epilepsy Patient Experience Through Social Media and Web-Based Forums
04/05/25
Phase 1 Multiple-Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator
04/05/25
A Modern Design for a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy With Generalized Tonic–Clonic Seizures
12/10/24
The Novel Antiseizure Therapeutic BHV-7000 Demonstrates Antidepressant and Impulse Control Properties in Preclinical Operant Models
12/06/2024
Functional effects of the M-current activator BHV-7000 on 50 epilepsy-associated KCNQ2 variants
12/06/2024
Phase 1 Multiple-Ascending Dose Studies Demonstrate Favorable Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator
12/06/2024
Pharmacological Characterization of BHV-7000, a Novel and Selective Activator of Kv7.2/Kv7.3 Channels, Using All-Optical Electrophysiology
12/06/2024
A Qualitative Assessment of the Epilepsy Patient Experience Through Social Media and Web-Based Forums
12/05/2024
A Modern Design for a Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BHV-7000 in Idiopathic Generalized Epilepsy With Generalized Tonic–Clonic Seizures
11/11/2024
BHV-7000, a Novel, Selective Kv7 Potassium Channel Activator, in Late-Stage Development for Major Depressive Disorder and Bipolar Disorder
09/07/2024
Patient Outcomes in KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE): Systematic Literature Review
09/07/2024
BHV-7000, A Novel, Selective Kv7.2/7.3 Potassium Channel Activator, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
09/07/2024
Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator: Results From Phase 1 Single-and Multiple-Ascending Dose Studies
09/07/2024
Understanding Lived Experiences with KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE)
06/29/2024
Patient Outcomes in KCNQ2 Developmental and Epileptic Encephalopathy (KCNQ2-DEE): Systematic Literature Review
06/29/2024
Understanding Lived Experiences with KCNQ2-Developmental and Epileptic Encephalopathy (KCNQ2-DEE)
06/29/2024
Safety, Tolerability, and Pharmacokinetics of BHV-2100, a First-in-Class TRPM3 Antagonist for Pain
06/29/2024
BHV-7000, A Novel, Selective Kv7.2/7.3 Potassium Channel Activator, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
5/29/2024
Safety and Tolerability of BHV-7000, a Novel Kv7 Potassium Channel Activator: Results from Phase 1 Single and Multiple Ascending Dose Studies
04/14/2024
Functional Impairments in Patients with KCNQ2-DEE: Associations Among Key Clinical Features
04/16/2024
Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults
04/16/2024
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
04/17/2024
Characterization of BHV-7000: A Novel Kv7/2/7.3 Activator for the Treatment of Seizures
04/17/2024
Determinants of Health-related Quality of Life of Patients with Focal Epilepsy: A Systematic Literature Review
12/01/2023
Determinants of Health-Related Quality of Life of Patients With Focal Epilepsy: A Systematic Literature Review
12/01/2023
Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Seizures
12/01/2023
Novel, Selective Kv7.2/7.3 Potassium Channel Activator, BHV-7000, Demonstrates Dose-Dependent Pharmacodynamic Effects on EEG Parameters in Healthy Adults
12/01/2023
Functional Impairments in Patients With KCNQ2-DEE: Associations Among Key Clinical Features
12/01/2023
A First in Human Phase 1 Study Evaluating the Safety and Tolerability of BHV-7000, a Novel, Selective Kv7.2/7.3 Potassium Channel Activator, in Healthy Adults
09/02/2023
Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy
03/13/2023
Discovery and Characterization of BHV-7000: A Novel Kv7.2/7.3 Activator for the Treatment of Epilepsy
12/03/2022
Effects of retigabine and the novel M-current activator BHV-7000 on epilepsy-associated KCNQ2 variants
6/15/2024
First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of the First-in-Class TRPM3 Antagonist BHV-2100 in Development for Migraine and Pain
04/05/25
BHV-8000, a selective brain-penetrant TYK2/JAK1 inhibitor for neuroinflammatory and neurodegenerative diseases, demonstrates favorable pharmacokinetics/pharmacodynamics and safety in phase 1 studies
04/05/25
Re-Weighting MDS-UPDRS Part II and PDQ-39 Items to Detect Maximal Decline in Activities of Daily Living in Untreated Parkinson’s Disease
04/05/25
Re-Weighting MDS-UPDRS Parts II and III Items to Improve Assessment of Motor Decline in Untreated Parkinson’s Disease
04/05/25
BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Efficacy in an Alpha-Synuclein Overexpressing Parkinson’s Disease Mouse Model
10/30/24
BHV-8000, a Selective Brain-Penetrant TYK2/JAK1 Inhibitor in Development for Neuroinflammatory and Neurodegenerative Diseases, Demonstrates Favorable PK/PD and Safety Profile in Phase 1 Studies
04/14/2024
Association of Anti-inflammatory Therapy Use with the Incidence of Parkinson's Disease: A Person-Time Analysis Among Patients with Autoimmune Diseases
04/14/2024
Re-weighting MDS-UPDRS Motor Items for Optimal Sensitivity to Parkinson's Disease Progression in Untreated Patients Using Parkinson's Progression Markers Initiative Data
04/17/2024
Re-weighting MDS-UPDRS Part II Items for Optimal Sensitivity to Parkinson's Disease Progression Using Parkinson's Progression Markers Initiative Natural History Data
3/8/2024
Association of Anti-Inflammatory Therapy Use With the Incidence of Parkinson’s Disease: A Person-Time Analysis Among Patients With Autoimmune Diseases
3/8/2024
Weighting MDS-UPDRS motor items for optimal sensitivity to Parkinson’s Disease progression in untreated patients using Parkinson’s Progression Markers Initiative data
3/8/2024
Weighting MDS-UPDRS Part II items for optimal sensitivity to Parkinson’s disease progression using Parkinson’s Progression Markers Initiative natural history data
11/15/24
Molecular Degraders of Extracellular Proteins (MoDEsTM) Rapidly and Effectively Remove Interstitial IgG and Disease-Relevant Immune Complexes Through Endolysosomal Degradation in the Liver
04/18/2024
Novel Bispecific Degrader BHV-1300 Achieves Rapid, Robust, and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates
04/05/25
Novel Bispecific Degrader BHV-1310 Achieves Rapid, Robust and Selective IgG Reduction in Preclinical Models Including Nonhuman Primates
04/05/25
Novel Bispecific Degrader BHV-1310 Eliminates Intravascular and Interstitial IgG in Multiple Organs and Anatomical Structures, Including the Neuromuscular Junction
10/25/24
First-in-class, antigen-specific extracellular protein degrader BHV-1400, in development for treating IgA nephropathy, selectively targets galactose-deficient IgA for rapid and efficient endolysosomal degradation in the liver
03/19/2024
BHV-1400 Targets the Non-Immunosuppressive, Selective Depletion of Circulating Galactose-Deficient IGA1 in IGA Nephropathy
12/09/2023
Expansion, Persistence, and Characteristics of Autologous, BHV-1100 ARMored Memory-Like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+, Multiple Myeloma Patients
09/27/2023
Expansion, Persistence, and Characteristics of Autologous, BHV-1100 ARMored Memory-Like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+, Newly Diagnosed Multiple Myeloma Patients